Manhattan Clinical Research

Manhattan Clinical Research is a dedicated research group specializing in gastrointestinal disorders, with a robust track record of participation in clinical trials that have paved the way for the approval of microbiome replacement therapies. Our research encompasses a wide range of conditions, including inflammatory bowel disease (IBD), celiac disease, and various gastrointestinal and liver disorders. Notably, we have contributed to investigator-initiated trials, such as a landmark study on IBS patients utilizing fecal microbiota transplantation (FMT), which was published in The Lancet. At MCR, we recognize the importance of introducing new therapies to the market, especially given that no single medication is effective for all patients with IBD. We are particularly enthusiastic about exploring the role of the microbiome in IBD and the promising treatment options that may arise from a deeper understanding of this complex ecosystem. Currently, we are actively enrolling patients with ulcerative colitis to investigate whether alterations in the microbiome could lead to improved disease management and outcomes.